Horizon Therapeutics
NEWS
Horizon Therapeutics was acquired by Amgen in 2023.
Horizon Therapeutics, Eli Lilly, Gilead Sciences and more hit financial road bumps or missed the mark entirely in their Q2 earnings reports.
The life science industry is growing rapidly, and many companies have announced expansions and job creation. Still, others have been forced to cut costs and slash jobs. For that and more, continue reading.
Horizon Therapeutics’ Bill Rees spoke to BioSpace about the scientific discovery and collaboration potential of its new Rockville, Maryland site, which is expected to open in 2024.
It was a busy, busy week for clinical trial news and updates, largely driven by the annual ASCO meeting taking place June 3-7 in Chicago.
Horizon Therapeutics announced its Phase II dazodalibep (HZN-4920) clinical trial has met its primary endpoint. Dazodalibep is a treatment for patients with Rheumatoid Arthritis (RA).
The FDA places holds, companies receive clearance for new studies and Pharma giants release new data in last week’s clinical trial news.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Going through the most newsworthy stories of the year, BioSpace found trends more than one big story, topics that just kept rising again and again. Here’s a look.
The agreement between the two companies includes a lead, potential first-in-class preclinical candidate, and research collaboration to jointly develop the additional novel candidates.
IN THE PRESS